| |
|
| Source: Company documents |
|
| Name
: |
Elizabeth A. Olek |
| Title
: |
Vice President and Chief Medical Officer |
| Since: |
12/03/2007 |
|
|
|
| Name
: |
Michael D. Kishbauch |
| Title
: |
President, Chief Executive Officer, Director |
| Since: |
07/2004 |
|
|
|
| Name
: |
Mary K. Fenton |
| Title
: |
Chief Financial Officer, Vice President |
| Since: |
10/2000 |
|
|
|
| Name
: |
Milind S. Deshpande |
| Title
: |
Executive Vice President - Research, Chief Scientific Officer |
| Since: |
09/2001 |
|
|
|
| Name
: |
Gautam Shah |
| Title
: |
Senior Vice President, Chief Compliance Officer |
| Since: |
05/2004 |
|
|
|
|
| Name
: |
Jason S. Fisherman M.D. |
| Title
: |
Director |
| Since: |
03/2000 |
|
|
|
|
| Name
: |
Jean-Francois Formela M.D. |
| Title
: |
Director |
| Since: |
01/2000 |
|
|
|
|
|
|
|
| |
|
| Earnings
Release Dates : 7th May 2008 , 27th February 2008 , 27th March 2007 |
|
 Audio |
|
|
| |
|
| |
|
| |
| Home Inns Opens Up 72% Oct 30, 5:26 PM EST |
|
| |
Achillion Pharmaceuticals, Inc.
Within the anti-infective market, the Company is currently concentrating on the development of antivirals for the treatment of HIV infection and chronic hepatitis C and the development of antibacterials for the treatment of serious hospital-based bacterial infections. The Company has advanced its lead drug candidate, elvucitabine for the treatment of HIV infection, into phase II clinical trials and its second clinical-stage drug candidate, ACH-806 for the treatment of chronic hepatitis C, into a phase I clinical trial in collaboration with Gilead Sciences.
|
| More... |
|
|
|
|
|
